Cardiovascular impact of electronic-cigarette use
Cardiovascular impact of electronic-cigarette use
复制标题
DOI：
10.1016/j.tcm.2019.04.006
复制
发表时间：
2020-04-01
影响因子：
9.3
通讯作者：
Middlekauff, Holly R.
中科院分区：
文献类型：
--
作者：
Middlekauff, Holly R.
与烟草卷烟（TC）相关的大多数过早死亡可归因于心血管疾病，因此，审查电子烟（EC）的总体心血管影响是合适和及时的，电子烟最近在烟草产品市场上爆炸式增长。对EC使用者的纵向研究是必要的，但尚未可用，以回答与TC吸烟者相比，慢性EC使用者的心血管疾病是否较低的问题，因此我们必须依赖于生物标志物研究。一些预示心血管风险增加的生物标志物，包括交感神经活动增加的标志物，氧化应激和炎症，血管功能障碍和血栓形成，已被报道在EC使用后异常，尽管通常没有达到TC吸烟者中发现的程度。我们的结论是，如果所有FDA认证的TC戒烟策略都没有成功，那么EC可能是TC戒烟的合理策略，但对非TC吸烟者的信息必须明确和坚定不移：非TC吸烟者不应该使用EC-它们不是无害的。(C)2019作者爱思唯尔公司出版
The majority of premature deaths related to tobacco cigarettes (TCs) are attributable to cardiovascular disease, so it is fitting and timely to review the overall cardiovascular impact of electronic cigarettes (ECs), which have recently exploded onto the tobacco product market. Longitudinal studies of EC users are necessary, but not yet available, to answer the question whether cardiovascular disease is lower in chronic EC users compared to TC smokers, so we must rely on biomarker studies. Several biomarkers that portend increased cardiovascular risk, including markers of increased sympathetic nerve activity, oxidative stress and inflammation, vascular dysfunction, and thrombosis, have been reported to be abnormal after EC use, although often not to the degree found in TC smokers. We conclude that if all FDA-certified strategies for TC smoking cessation have been tried without success, then ECs may be a reasonable strategy for TC smoking cessation, but the message to non-TC smokers must be clear and unwavering: non TC-smokers should not use ECs - they are not harmless. (C) 2019 The Author. Published by Elsevier Inc.